# Cardiotoxicity in Breast Cancer Patients

> **NCT06491680** · PHASE4 · RECRUITING · sponsor: **Helwan University** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT06491680
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-10
- **Primary completion:** 2025-10
- **Final completion:** 2026-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491680, "Cardiotoxicity in Breast Cancer Patients". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06491680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*